-The Economic Times CHENNAI: India's patent appeals board has denied Monsanto a patent for a genetically-engineered method of increasing climate resilience in plants. The decision is significant not only for Monsanto's loss of possible exclusivity in an increasingly important segment but also for the interpretation of India's home-grown clauses in patent law - these are unpopular with global companies - for the first time in the case of plants. The Intellectual Property...

-The Business Standard Angelina Jolie has inadvertently highlighted a key question about patenting Angelina Jolies recent double mastectomy was obviously a very radical decision. It is unusual for a healthy person to opt for pre-emptive surgery to avert the probability, however high it may be, of getting cancer. The tests Jolie relied on are also at the heart of a legal battle, which could affect US biotech patenting norms. Since the US...

-The Guardian Farms processing insects for animal feed might soon become global reality as demand grows for sustainable feed sources   The best way to feed the 9 billion people expected to be alive by 2050 could be to rear billions of common houseflies on a diet of human faeces and abattoir blood and grind them up to use as animal feed, a UN report published on Monday suggests. Doing so would...

-Frontline   The Supreme Court's ruling against Novartis' patent claim for the cancer drug Glivec paves the way for generic drug companies to keep crucial, life-saving drugs affordable to the common people. By V. VENKATESAN IN their 112-page judgment delivered on April 1, Justice Aftab Alam and Justice Ranjana Prakash Desai of the Supreme Court began with a simple proposition: in order to understand what the law really is, it is essential to...

-The Hindu     Drug patents are designed to create profits that enable more research on diseases affecting millions. But in practice, they have often generated super profits for big pharma companies while erecting access barriers for the poor. The Novartis case spotlights much that is wrong with the system. The rejection of the Novartis petition challenging one of the most progressive tenets of the Indian Patents Act (1970), as amended in 2005 by...